Systemic and Endocrine Effects of Endothelin in Humans

  • H. Vierhapper

Abstract

The endothelium is the key to a complex system of neural and humoral factors modulating vascular smooth muscle tone by producing both relaxing and constrictive factors including the three currently known members of the endothelin family, endothelin-1 (ET-1 [1]), ET-2 and ET-3. These three structurally related peptides correspond to two types of receptors, designated ETA and ETB. The hemodynamic effects of endothelin-1 have been extensively studied in various animal models. Furthermore an impressive bulk of data has been obtained in vitro and in vivo concerning the recently recognized importance of endothelins as regulatory factors in various endocrine tissues. Although endothelin-1 is secreted mainly abluminally [2] and may play a paracrine rather than an endocrine role, experiments evaluating the effects of pharmacological doses in man may help to interpret the effect of increased plasma concentrations of ET-1 which have been observed in various clinical conditions [3]. However, due to the difficulty arising from the use of such a potent vaso-pressor agent on an experimental basis in humans comparatively few such experiments have been performed in man.

Keywords

Cortisol Aspirin Arginine Angiotensin Histamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415PubMedCrossRefGoogle Scholar
  2. 2.
    Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W, Binder BR (1992) Polar Secretion of Endothelin-1 by Cultured Endothelial Cells. J Biol Chem 267:16 066–16 068Google Scholar
  3. 3.
    Hutchison FN (1989) Endothelin: a new role for an old friend? J Lab Clin Med 122: 126–127Google Scholar
  4. 4.
    Vierhapper H, Wagner O, Nowotny P, Waldhäusl W (1990) Effect of endothelin-1 in man. Circulation 81: 1415–1418PubMedCrossRefGoogle Scholar
  5. 5.
    Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA (1994) Effects of Endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 46: 376–381PubMedCrossRefGoogle Scholar
  6. 6.
    Sorensen SS, Madsen JK, Pedersen EB (1994) Systemic and renal effect of intravenous infusion of endothelin-i in healthy human volunteers. Am J Physiol 266: F411 - F418PubMedGoogle Scholar
  7. 7.
    Goetz KL, Wang BC, Madwed JB, Zhu JL, Leadley RJ (1988) Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. Am J Physiol 255: R1064 - R1068PubMedGoogle Scholar
  8. 8.
    Vierhapper H, Wagner OF, Nowotny P, Waldhäusl W (1992) Effect of endothelin-i in man: pretreatment with nifedipine, with indomethacin and with cyclosporine A. Eur J Clin Invest 22: 55–59PubMedCrossRefGoogle Scholar
  9. 9.
    Donckier JE, Hanet C, Berbinschi A, Galanti L, Robert A, Van Mechelen H, Pouleur H, Ketelslegers J-M (1991) Cardiovascular and endocrine effects of endothelin-i at pathophysiological and pharmacologica plasma concentrations in conscious dogs. Circulation 84: 2476–2484PubMedGoogle Scholar
  10. 1o.
    Webb DJ, Haynes WG (1993) Venoconstriction to endothelin-i in humans is attenuated by local generation of prostacyclin but not nitric oxide. J Cardiovasc Pharmacol 22: 5317–5320CrossRefGoogle Scholar
  11. 11.
    Haynes WG, Webb DJ (1993) Venoconstriction to endothelin-i in humans: role of calcium and potassium channels. Am J Phyciol 265: H1676 - H1681Google Scholar
  12. 12.
    Blöchl-Daum B, Vierhapper H, Eichler H-G, Waldhäusl W (1992) Endothelin-induced venoconstriction is unaffected by type 2-diabetes: in vivo effect of histamine on the endothelin action on veins. Arch Int Pharmacodyn 316: 90–96PubMedGoogle Scholar
  13. 13.
    Kiowski W, Löscher TF, Linder L, Bühler FR (1991) Endothelin-i-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 83: 469–475Google Scholar
  14. 14.
    Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, Bühler FR (1994) Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-i in clinically healthy smokers. Circulation 90: 27–34PubMedGoogle Scholar
  15. 15.
    Dahlöf B, Gustafsson D, Hedner T, Jern S, Hansson L (1990) Regional haemodynamic effects of endothelin-i in rat and man: unexpected adverse reaction. J Hypertens 8: 811–817PubMedCrossRefGoogle Scholar
  16. 16.
    Vierhapper H, Hollenstein U, Roden M, Nowotny P (1993) Effect of endothelin-, in man - impact on basal and stimulated concentrations of LH, FSH, TSH, GH, ACTH and PRL. Metabolism 42: 902–906Google Scholar
  17. 17.
    Nayler WG, Gu XH, Casley DJ, Panagitopoulos S, Liu J, Mottram PL (1990) Cyclosporine increases endothelin-i binding site density in cardiac cell membranes. Biochem Biophys Res Commun 163: 1270–1274CrossRefGoogle Scholar
  18. 18.
    Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhäusl W (1992) Regional effects and clearance of endothelin-i across pulmonary and splanchnic circulation. Eur J Clin Invest 22: 277–282PubMedCrossRefGoogle Scholar
  19. 19.
    Weitzberg E, Ahlborg G, Lundberg JM (1993) Differences in vascular effects and removal of endothelin-i in human lung, brain, and skeletal muscle. Clin Physio113: 653–662Google Scholar
  20. 20.
    Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhäusl W (1992) Regional hemodynamic effects and clearance of endothelin-i in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 19: 176–180PubMedCrossRefGoogle Scholar
  21. 21.
    Wagner OF, Nowotny P, Vierhapper H, Waldhäusl W (1990) Determination of endothelin-i in human plasma: arterio-venous differences and release during venous stasis. Eur J Clin Invest 20: 502–505PubMedCrossRefGoogle Scholar
  22. 22.
    Druml W, Steltzer H, Waldhäusl W, Lenz K, Hammerle A, Vierhapper H, Gasic S, Wagner OF (1993) Endothelin-i in adult respiratory distress syndrome. Am Rev Respir Dis 148: 1169–1173PubMedGoogle Scholar
  23. 23.
    Cozza EN, Gomez-Sanchez CE, Foecking MF, Chiou S (1989) Endothelin binding to cultured adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest 84: 1032–1035PubMedCrossRefGoogle Scholar
  24. 24.
    Rosolowsky LJ, Campbell WB (1990) Endothelin enhances adrenocorticotropin-stimulated aldosterone release from cultured bovine adrenal cells. Endocrinology 126: 1860–1866PubMedCrossRefGoogle Scholar
  25. 25.
    Vierhapper H, Nowotny P, Waldhäusl W (1995) Effect of endothelin-i in man–impact on basal and ACTH-stimulated concentrations of aldosterone. J Clin Endocrin Metab 80: 948–951CrossRefGoogle Scholar
  26. 26.
    Takahashi K, Ghatei MA, Jones PM, Murphy JK, Lam H-C, O’Halloran DJ, Bloom SR (1991) Endothelin in human brain and pituitary gland. Presence of immunoreactive endothelin, endothelin messenger ribonucleic acid, and endothelin receptors. J Clin Endocrinol Metab 72: 693–699PubMedCrossRefGoogle Scholar
  27. 27.
    Samson WK, Skala KD, Alexander BD, Huang F-L S (1990) Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro. Biochem Biophys Res Comm 169: 737–743PubMedCrossRefGoogle Scholar
  28. 28.
    Stojilkovic SS, Merelli F, Iida T, Krsmanovic LZ, Catt KJ (1990) Endothelin stimulation of cytosolic calcium and gonadotropin secretion in anterior pituitary cells. Science 248: 1663–1666PubMedCrossRefGoogle Scholar
  29. 29.
    Hirai M, Miyabo S, Ooya E, Miyanaga K, Aoyagi N, Kimura K, Kishida S, Nakai T (1991) Endothelin-3 stimulates the hypothalamic-pituitary-adrenal axis. Life Sci 48: 2359–2263PubMedCrossRefGoogle Scholar
  30. 30.
    Moretto M, Lopez FJ, Negro-Vilar A (1993) Endothelin-3 stimulates luteinizing hormone-releasing hormone ( LHRH) secretion from LHRH neurons by a prostaglandin-dependent mechanism. Endocrinology 132: 789–794PubMedCrossRefGoogle Scholar
  31. 31.
    Hirata Y, Matsunaga T, Ando K, Furukawa T, Tsukagoshi H, Marumo F (1990) Presence of endothelin-i-like immunoreactivity in human cerebrospinal fluid. Biochem Biophys Res Commun 166: 1274–1278PubMedCrossRefGoogle Scholar
  32. 32.
    Yamaji T, Johshita H, Ishibashi M, Takaku F, Ohno H, Suzuki N, Matsumoto H, Fujino M (1990) Endothelin family in human plasma and cerebrospinal fluid. J Clin Endocrinol Metab 71: 1611–1615PubMedCrossRefGoogle Scholar
  33. 33.
    Kanyicska B, Burris TP, Freeman ME (1991) Endothelin-3 inhibits prolactin and stimulates LH, FSH and TSH secretion from pituitary cell culture. Biochem Biophys Res Commun 174: 338–343PubMedCrossRefGoogle Scholar
  34. 34.
    Vierhapper H, Hollenstein U, Gessl A, Roden M, Nowotny P, Waldhäusl W (1994) Effect of endothelin-i on basal and stimulated concentrations of pituitary hormones in healthy men with and without pretreatment with nifedipine. 38th symposium, Deutsche Gesellschaft für Endokrinologie, Würzburg, 2–5 March 1994. Exp Clin Endocrinol 102 [Suppl 1]: 116 (abstract)Google Scholar
  35. 35.
    Gross PM, Wainman DS, Espinosa FJ (1991) Differentiated metabolic stimulation of rat pituitary lobes by peripheral and central endothelin-i. Endocrinology 129: 1110–1112PubMedCrossRefGoogle Scholar
  36. 36.
    Calogero AE, Raiti F, Nicolosi G, Burrello N, D’Agata R, Mantero F (1994) Effects of endothelin-i and endothelin-3 on rat hypothalamic corticotrophin-releasing hormone and pituitary ACTH release in vitro. J Endocrinol 140: 419–424PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • H. Vierhapper

There are no affiliations available

Personalised recommendations